[go: up one dir, main page]

CO5080752A1 - INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB - Google Patents

INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB

Info

Publication number
CO5080752A1
CO5080752A1 CO99037918A CO99037918A CO5080752A1 CO 5080752 A1 CO5080752 A1 CO 5080752A1 CO 99037918 A CO99037918 A CO 99037918A CO 99037918 A CO99037918 A CO 99037918A CO 5080752 A1 CO5080752 A1 CO 5080752A1
Authority
CO
Colombia
Prior art keywords
group
aryl
alkyl
transcription factor
factor inhibitors
Prior art date
Application number
CO99037918A
Other languages
English (en)
Inventor
James Francis Callahan
Fletcher Marie C Chabot
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5080752A1 publication Critical patent/CO5080752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Una composición farmacéutica que comprende un compuesto de fórmula I:<EMI FILE="99037918_1" ID="1" IMF=JPEG >En la que:R1 es arilo;R2 se selecciona entre el grupo que consta de: H, alquilo C1-6 y arilo;R3 se selecciona entre el grupo que consta de: alquilo C1-6 y cicloalquilo C3-8; y R2 y R3 pueden ser unidos conjuntamente para formar un anillo heterocíclico de 5-7 átomos seleccionados entre le grupo que consta de: C, N, O y S; y un vehículo, diluyente o excipiente farmacéuticamente aceptable.Un método para inhibir el NF-kB que comprende administrar a un paciente que necesita de ello una cantidad eficaz de un compuesto de fórmula I:<EMI FILE="99037918_2" ID="2" IMF=JPEG >en la que:R1 es arilo;R2 se selecciona entre el grupo que consta de: H, alquilo C1-6 y arilo;R3 se selecciona entre el grupo que consta de : alquilo C1-6 y cicloalquilo C3-8 ; yR2 y R3 pueden ser unidos conjuntamente para formar un anillo heterocíclico de 5-7 átomos, seleccionados entre el grupo que consta de: C, N, O y S.
CO99037918A 1998-06-19 1999-06-17 INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB CO5080752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
CO5080752A1 true CO5080752A1 (es) 2001-09-25

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99037918A CO5080752A1 (es) 1998-06-19 1999-06-17 INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB

Country Status (17)

Country Link
EP (1) EP1085872A4 (es)
JP (1) JP2002518333A (es)
KR (1) KR20010052990A (es)
CN (1) CN1306428A (es)
AR (1) AR019871A1 (es)
AU (1) AU4699699A (es)
BR (1) BR9911151A (es)
CA (1) CA2335293A1 (es)
CO (1) CO5080752A1 (es)
CZ (1) CZ20004760A3 (es)
HU (1) HUP0102492A2 (es)
IL (1) IL140324A0 (es)
NO (1) NO20006452L (es)
PL (1) PL345577A1 (es)
TR (1) TR200003779T2 (es)
WO (1) WO1999065495A1 (es)
ZA (1) ZA200007448B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2328140C (en) 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity
IL150763A0 (en) * 2000-01-24 2003-02-12 Genzyme Corp Jak/stat inhibitors and pharmaceutical compositions containing the same
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US7812018B2 (en) 2006-02-16 2010-10-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
WO2011014825A2 (en) 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
US10160705B2 (en) 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en) 2012-10-31 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
ZA200007448B (en) 2001-12-12
HUP0102492A2 (hu) 2001-11-28
KR20010052990A (ko) 2001-06-25
AR019871A1 (es) 2002-03-20
NO20006452L (no) 2001-02-16
BR9911151A (pt) 2001-03-06
EP1085872A4 (en) 2003-04-16
IL140324A0 (en) 2002-02-10
CA2335293A1 (en) 1999-12-23
JP2002518333A (ja) 2002-06-25
WO1999065495A1 (en) 1999-12-23
EP1085872A1 (en) 2001-03-28
PL345577A1 (en) 2001-12-17
NO20006452D0 (no) 2000-12-18
CZ20004760A3 (cs) 2001-08-15
CN1306428A (zh) 2001-08-01
TR200003779T2 (tr) 2001-06-21
AU4699699A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
CA2494613A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
CA2386515A1 (en) Piperazine derivatives
CO5280060A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
GEP20053454B (en) Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof
KR927003520A (ko) 펩티딜(peptidyl) 유도체
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
NO20025118D0 (no) Dipeptylpeptidase IV-inhibitorer
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
NO974695D0 (no) Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer
CA2475619A1 (en) Piperidine derivatives
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
CO5160292A1 (es) Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
AR044175A1 (es) Compuestos de cefemo
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
RU94044357A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования увеличения веса, индуцирования снижения веса или ингибирования аппетита
AR032598A1 (es) Oxazinquinolonas, una composicion farmaceutica y el uso de las mismas para preparar un medicamento utiles en el tratamiento de infecciones virales
ES2262504T3 (es) Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
AU8519601A (en) 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents